Trimethoprim-sulfamethoxazole (TMP-SMX, co-trimoxazole, or bactrim) has been the standard first-line treatment against Pneumocystis jirovecii pneumonia (PCP) for decades. However, adverse effects and cases of treatment failure have led to a search for alternative agents. We present a case of a 50 year old immune compromised female whose course of PCP did not improve until Caspofungin was added to TMP-SMX.
Download full-text PDF |
Source |
|---|---|
| http://www.ncbi.nlm.nih.gov/pmc/articles/PMC6384316 | PMC |
| http://dx.doi.org/10.1016/j.idcr.2019.e00496 | DOI Listing |
Publication Analysis
Top Keywords
combination therapy
4
therapy trimethoprim-sulfamethoxazole
4
trimethoprim-sulfamethoxazole caspofungin
4
caspofungin case
4
case severe
4
severe pneumocystis
4
pneumocystis pneumonia
4
pneumonia trimethoprim-sulfamethoxazole
4
trimethoprim-sulfamethoxazole tmp-smx
4
tmp-smx co-trimoxazole
4
Similar Publications
Want AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!